Frank F. Seghatol-Eslami
Frank F. Seghatol-Eslami has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Kan Liu
Division of Cardiology, Washington University in St Louis, St. Louis, Missouri
2 shared publications - Amanda Chang
Department of Internal Medicine (A.C.), University of Iowa
1 shared publication - Christian Templin
Department of Cardiology and Internal Medicine B, University Medicine Greifswald, Germany (D.D.V., C.T.).
1 shared publication Crystal Licari
Cardiovascular Division, Department of Internal Medicine, Washington University in St. Louis, MO (F.S.-E., S.J.K., Y.C., C.L., S.V., K.L.).
1 shared publicationDavide Di Vece
Department of Cardiology and Internal Medicine B, University Medicine Greifswald, Germany (D.D.V., C.T.).
1 shared publicationDilip S. Nath
Department of Cardiothoracic Surgery, Washington University School of Medicine and Children Hospital, St. Louis, Missouri
1 shared publication
Latest Publications
- 11 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
Motion-Informed Neural Network Towards Diastolic Mechanics in Takotsubo Syndrome
BACKGROUND: The pathophysiology of Takotsubo syndrome (TTS) remains perplexing. We developed a motion-informed neural network (MiNN-Echo) using echocardiograms to elucidate the diastolic mechanics of TTS. METHODS: We trained and validated MiNN-Echo, a deep convolutional neural network (2D+t) echocardiographic prediction model using multi-vendor echocardiograms from 1142 patients (596 TTS and 546 anterior myocardial infarction) in a multi-institutional cohort. A total of 68 expert echocardiographic readers performed human interpretation. The network’s dual-branch architecture independently learns spatial and temporal features, using 2-dimensional image frames for spatial representation and segmentation, and optical flow with sinusoidal phase encoding for temporal dynamics. The MiNN-Echo model integrates static cardiac anatomic changes with motion details from 2-dimensional echocardiographic videos to produce interpretable disease predictions. RESULTS: The MiNN-Echo model achieved an area under the curve of 0.77, compared with 0.69 among human readers in differentiating TTS from acute myocardial infarction. Myocardial motion features during diastole contributed more (≈71%) to the differential diagnosis than those during systole. Compared with patients with acute myocardial infarction, TTS patients showed increased isovolumic relaxation time (112.5 [interquartile range (IQR), 68.75–165.94] ms versus 87.5 [IQR, 54.17–140] ms, P P P P P =0.006), passive (0.45 [IQR, 0.33–0.58] versus 0.50 [IQR, 0.38–0.68]; P P =0.001) phases, and altered rotation angles (away from the horizontal A–V plane) in the passive ventricular filling phase (−70.19 [IQR, −89.62 to −41.33] versus −60.34 [IQR, −87.07 to −30.84]; P =0.020). CONCLUSIONS: MiNN-Echo in echocardiograms elucidates unique myocardial relaxation kinematics to characterize TTS-associated diastolic mechanics.
- 11 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
Motion-Informed Neural Network Towards Diastolic Mechanics in Takotsubo Syndrome
BACKGROUND: The pathophysiology of Takotsubo syndrome (TTS) remains perplexing. We developed a motion-informed neural network (MiNN-Echo) using echocardiograms to elucidate the diastolic mechanics of TTS. METHODS: We trained and validated MiNN-Echo, a deep convolutional neural network (2D+t) echocardiographic prediction model using multi-vendor echocardiograms from 1142 patients (596 TTS and 546 anterior myocardial infarction) in a multi-institutional cohort. A total of 68 expert echocardiographic readers performed human interpretation. The network’s dual-branch architecture independently learns spatial and temporal features, using 2-dimensional image frames for spatial representation and segmentation, and optical flow with sinusoidal phase encoding for temporal dynamics. The MiNN-Echo model integrates static cardiac anatomic changes with motion details from 2-dimensional echocardiographic videos to produce interpretable disease predictions. RESULTS: The MiNN-Echo model achieved an area under the curve of 0.77, compared with 0.69 among human readers in differentiating TTS from acute myocardial infarction. Myocardial motion features during diastole contributed more (≈71%) to the differential diagnosis than those during systole. Compared with patients with acute myocardial infarction, TTS patients showed increased isovolumic relaxation time (112.5 [interquartile range (IQR), 68.75–165.94] ms versus 87.5 [IQR, 54.17–140] ms, P P P P P =0.006), passive (0.45 [IQR, 0.33–0.58] versus 0.50 [IQR, 0.38–0.68]; P P =0.001) phases, and altered rotation angles (away from the horizontal A–V plane) in the passive ventricular filling phase (−70.19 [IQR, −89.62 to −41.33] versus −60.34 [IQR, −87.07 to −30.84]; P =0.020). CONCLUSIONS: MiNN-Echo in echocardiograms elucidates unique myocardial relaxation kinematics to characterize TTS-associated diastolic mechanics.
- Open Access
- 8 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 28173
Tricuspid Regurgitation: A Comprehensive Review of Clinical, Imaging and Therapy
Once considered the “forgotten valve and ventricle”, the tricuspid valve and right ventricle are now recognized as critical structures with significant clinical and prognostic implications. Growing evidence has highlighted that tricuspid regurgitation (TR) and right heart failure are not merely secondary phenomena that resolve following the treatment of left-sided heart disease. Instead, TR and right heart failure contribute to adverse outcomes and increased mortality if left untreated. This paradigm shift has fueled extensive clinical research, leading to a deeper understanding of the pathophysiology of TR and right ventricular (RV) dysfunction. Additionally, advancements in cardiovascular imaging have facilitated early detection, risk stratification, and innovative therapeutic approaches for TR and right heart failure. This article explores the evolving landscape of tricuspid valve disease, emphasizing the importance of early recognition and the role of emerging imaging technologies in improving patient outcomes. Thanks to progress in imaging technology, especially echocardiography, as well as cardiac magnetic resonance and cardiac computer tomography, enhanced studies can be conducted on the tricuspid valve pathology to delineate the various mechanisms involved in TR and RV dysfunction and offer patients a tailored medical, as well as surgical and transcatheter therapies. These unparalleled technological advances would not be possible without the hard work of physicians, scientists, surgeons, interventional cardiologists, and echocardiographers worldwide, despite the many challenges they experience daily and in every procedure. Many patients with TR present at an advanced stage of disease progression, often with severe regurgitation and clinical manifestations associated with poor outcomes. Additionally, a significant proportion of these patients have either undergone previous open-heart surgery for left-sided valvular disease or are considered high-risk surgical candidates due to multiple comorbid conditions. In recent years, transcatheter therapy has emerged as a viable alternative for this high-risk population, offering a less invasive option for those previously deemed “inoperable”. This breakthrough has transformed the therapeutic landscape for valvular heart disease, particularly for TR, providing new hope and improved outcomes for patients who were once left with limited treatment options.
- 8 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 28173
Open AccessTricuspid Regurgitation: A Comprehensive Review of Clinical, Imaging and Therapy
Once considered the “forgotten valve and ventricle”, the tricuspid valve and right ventricle are now recognized as critical structures with significant clinical and prognostic implications. Growing evidence has highlighted that tricuspid regurgitation (TR) and right heart failure are not merely secondary phenomena that resolve following the treatment of left-sided heart disease. Instead, TR and right heart failure contribute to adverse outcomes and increased mortality if left untreated. This paradigm shift has fueled extensive clinical research, leading to a deeper understanding of the pathophysiology of TR and right ventricular (RV) dysfunction. Additionally, advancements in cardiovascular imaging have facilitated early detection, risk stratification, and innovative therapeutic approaches for TR and right heart failure. This article explores the evolving landscape of tricuspid valve disease, emphasizing the importance of early recognition and the role of emerging imaging technologies in improving patient outcomes. Thanks to progress in imaging technology, especially echocardiography, as well as cardiac magnetic resonance and cardiac computer tomography, enhanced studies can be conducted on the tricuspid valve pathology to delineate the various mechanisms involved in TR and RV dysfunction and offer patients a tailored medical, as well as surgical and transcatheter therapies. These unparalleled technological advances would not be possible without the hard work of physicians, scientists, surgeons, interventional cardiologists, and echocardiographers worldwide, despite the many challenges they experience daily and in every procedure. Many patients with TR present at an advanced stage of disease progression, often with severe regurgitation and clinical manifestations associated with poor outcomes. Additionally, a significant proportion of these patients have either undergone previous open-heart surgery for left-sided valvular disease or are considered high-risk surgical candidates due to multiple comorbid conditions. In recent years, transcatheter therapy has emerged as a viable alternative for this high-risk population, offering a less invasive option for those previously deemed “inoperable”. This breakthrough has transformed the therapeutic landscape for valvular heart disease, particularly for TR, providing new hope and improved outcomes for patients who were once left with limited treatment options.